FDA Voices Concern Over St. Jude (STJ) Durata Lead Testing; Shares Fall
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/11/2026
- Wall St set to gain on tech rebound, Middle East in focus
- SpaceX prices historic IPO at $135/share in largest ever new listing
- Oil drops as Trump cancels planned strikes against Iran
- Intel rallies as BofA double-upgrades stock on increased CPU, foundry visibility
- Oppenheimer sees little strategic case for Tesla-SpaceX merger
- Needham Starts Hyliion Holdings (HYLN) at Buy
- Adobe CFO Dan Durn to depart company in June 2026
- Oppenheimer Starts SpaceX (SPCX) at Outperform, PT $190, 'space infrastructure appears structurally advantaged'
- Pentagon reportedly locked down, hazmat teams responding
- Alibaba falls on China AI capex report; Citi says selloff is premature
Wells Fargo Downgrades St. Jude Medical (STJ) to Market Perform
November 21, 2012 6:46 AM ESTWells Fargo downgraded St. Jude Medical (NYSE: STJ) from Outperform to Market Perform and cut its price target range from $49-$50 to $25-$36.
The firm comments, "Although we expected the noise level around STJ's Riata/Durata ICD leads to subside,... More
